Morgan Stanley’s Xilio Therapeutics XLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $982K | Buy |
1,444,326
+288,488
| +25% | +$196K | ﹤0.01% | 5109 |
|
|
2025
Q1 | $837K | Buy |
1,155,838
+154,479
| +15% | +$112K | ﹤0.01% | 5090 |
|
|
2024
Q4 | $956K | Sell |
1,001,359
-520,743
| -34% | -$497K | ﹤0.01% | 5118 |
|
|
2024
Q3 | $1.2M | Buy |
1,522,102
+409,362
| +37% | +$322K | ﹤0.01% | 4941 |
|
|
2024
Q2 | $1.05M | Buy |
1,112,740
+890,835
| +401% | +$844K | ﹤0.01% | 4929 |
|
|
2024
Q1 | $240K | Sell |
221,905
-32,625
| -13% | -$35.2K | ﹤0.01% | 5668 |
|
|
2023
Q4 | $140K | Buy |
254,530
+228,265
| +869% | +$126K | ﹤0.01% | 6059 |
|
|
2023
Q3 | $55.4K | Sell |
26,265
-751
| -3% | -$1.59K | ﹤0.01% | 6124 |
|
|
2023
Q2 | $70.8K | Sell |
27,016
-3,523
| -12% | -$9.23K | ﹤0.01% | 6082 |
|
|
2023
Q1 | $96.8K | Buy |
30,539
+4,928
| +19% | +$15.6K | ﹤0.01% | 6015 |
|
|
2022
Q4 | $68.9K | Buy |
25,611
+18,771
| +274% | +$50.5K | ﹤0.01% | 6145 |
|
|
2022
Q3 | $20K | Sell |
6,840
-200
| -3% | -$585 | ﹤0.01% | 6800 |
|
|
2022
Q2 | $20K | Buy |
7,040
+4,936
| +235% | +$14K | ﹤0.01% | 6993 |
|
|
2022
Q1 | $14K | Buy |
2,104
+1,066
| +103% | +$7.09K | ﹤0.01% | 7289 |
|
|
2021
Q4 | $17K | Buy |
+1,038
| New | +$17K | ﹤0.01% | 7283 |
|